| Literature DB >> 31319865 |
Xuemei Liu1, Wei Zhang2, Yanping Xu2, Yongli Chu3, Xinrong Wang2, Qian Li4, Zhi Ma2, Zhenteng Liu2, Yanling Wan2.
Abstract
BACKGROUND: Vitamin D plays critical role in the female reproductive system. It seems that vitamin D is associated with clinical pregnancy outcomes of assisted reproductive technologies (ART), but its role remains elusive. This study is aimed to establish whether vitamin D is associated with clinical outcomes of in vitro fertilization (IVF).Entities:
Keywords: Clinical pregnancy rate; In vitro fertilization; Live birth rate; Vitamin D
Mesh:
Substances:
Year: 2019 PMID: 31319865 PMCID: PMC6639905 DOI: 10.1186/s12958-019-0500-0
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1Patient selection process
Patients and IVF cycle characteristics by serum 25 (OH) D quartiles
| Parameter | Group1 | Group2 | Group 3 | Group 4 | |
|---|---|---|---|---|---|
| Number of cycles | 216 | 210 | 211 | 211 | |
| Serum 25(OH) D (ng/ml) | |||||
| Median | 9.04 | 13.67 | 16.20 | 23.22 | |
| Range | 4.92–11.20 | 11.25–14.00 | 14.10–18.60 | 18.70–39.51 | |
| Age(y) | 31.65 ± 3.32 | 31.86 ± 3.94 | 31.31 ± 3.44 | 31.88 ± 3.69 | 0.331 |
| Duration of infertility(y) | 3.53 ± 2.19 | 3.85 ± 2.76 | 3.68 ± 2.31 | 3.61 ± 2.38 | 0.543 |
| BMI (kg/m2) | 23.93 ± 3.61 | 23.37 ± 3.30 | 23.16 ± 3.28 | 23.46 ± 3.33 | 0.099 |
| AMH (ng/ml) | 7.21 ± 5.50 | 6.05 ± 4.37 | 6.93 ± 5.61 | 6.68 ± 5.51 | 0.134 |
| bFSH (mIU/ml) | 6.75 ± 1.77 | 7.04 ± 2.03 | 6.88 ± 1.95 | 6.57 ± 1.68 | 0.063 |
| Season of blood drawing | |||||
| Spring (n, %) | 55,25.5% | 39,18.6% | 25,11.8% | 24,11.4% | <0.001* |
| Summer (n, %) | 78,36.1% | 71,33.8% | 55,26.1% | 41,19.4% | |
| Autumn (n, %) | 22,10.2% | 43,20.5% | 76,36.0% | 74,35.1% | |
| Winter (n, %) | 61,28.2% | 57,27.1% | 55,26.1% | 72,34.1% | |
| Previous pregnancy | |||||
| NO (n, %) | 106 (49.1%) | 87 (41.4%) | 111 (52.6%) | 103 (48.8%) | 0.134 |
| Yes (n, %) | 110 (50.9%) | 123 (58.6%) | 100 (47.4%) | 108 (51.2%) | |
| Infertility diagnosis | |||||
| Male factor ( | 5 (2.3%) | 11 (5.2%) | 10 (4.7%) | 10 (4.7%) | 0.837 |
| Tubal factor ( | 135 (62.8%) | 131 (62.4%) | 122 (57.8%) | 125 (59.2%) | |
| Mixed ( | 24 (11.2%) | 28 (13.3%) | 26 (12.3%) | 28 (13.3%) | |
| Endometriosis ( | 7 (3.3%) | 11 (5.2%) | 13 (6.2%) | 14 (6.6%) | |
| Anovulatory ( | 41 (19.1%) | 27 (12.9%) | 37 (17.5%) | 32 (15.2%) | |
| Unexplained ( | 3 (1.4%) | 2 (1.0%) | 3 (1.4%) | 2 (0.9%) | |
| COH protocol | |||||
| Luteal phase agonist ( | 151 (69.9%) | 143 (68.1%) | 159 (75.4%) | 158 (74.9%) | 0.250 |
| Antagonist ( | 65 (30.1%) | 67 (31.9%) | 52 (24.6%) | 53 (25.1%) | |
| Duration of stimulation (d) | 9.06 ± 2.17 | 9.04 ± 2.34 | 8.81 ± 2.20 | 9.05 ± 2.50 | 0.631 |
| Follicle≥16 mm on HCG day | 10.26 ± 4.94 | 9.01 ± 4.73 | 9.86 ± 5.55 | 9.68 ± 5.02 | 0.083 |
| Endometrial thickness on HCG day (mm) | 11.62 ± 2.71 | 11.30 ± 2.21 | 11.36 ± 2.32 | 11.49 ± 2.45 | 0.536 |
| Progestrone on HCG day (ng/ml) | 0.86 ± 0.28 | 0.90 ± 0.29 | 0.94 ± 0.34 | 0.94 ± 0.32 | 0.143 |
| Peak estradiol (pg/ml) | 3737.49 ± 2178.84 | 3398.98 ± 2227.44 | 3593.33 ± 2352.79 | 3569.79 ± 2231.67 | 0.540 |
| Oocytes retrieved ( | 11.47 ± 5.53 | 10.12 ± 4.78 | 10.79 ± 5.43 | 10.68 ± 5.56 | 0.078 |
| Mature oocytes ( | 9.45 ± 4.80 | 8.40 ± 4.14 | 9.05 ± 4.66 | 8.97 ± 4.54 | 0.119 |
| Normal fertilization rate (%) | 69.62 ± 17.85 | 71.69 ± 19.92 | 73.82 ± 18.36 | 75.43 ± 17.39 | 0.007* <0.001a* |
| High quality embryo rate (%) | 67.5% | 67.2% | 65.3% | 67.7% | 0.465 |
| Blastocyst formation rate (%) | 66.86 ± 28.60 | 62.48 ± 33.21 | 65.84 ± 31.27 | 67.96 ± 28.87 | 0.332 |
| Embryos transferred ( | 1.93 ± 0.26 | 1.92 ± 0.28 | 1.97 ± 0.18 | 1.95 ± 0.22 | 0.340 |
*Values are significantly different between groups (P < 0.05)
aAdjusted for maternal age, BMI, AMH, infertility diagnosis, season of blood draw, COH protocol, previous pregnancy, duration of stimulation, E2 levels on the day of hCG, number of larger follicles, number of oocytes retrieved and number of mature oocytes
Fig. 2Serum 25 (OH) D concentration were significantly higher in IVF group than R-ICSI group (P = 0.013)
Fig. 3The relationship of follicular fluid vitamin D levels and serum vitamin D levels. Follicular fluid vitamin D levels were positively correlated with serum vitamin D levels (r = 0.85, p < 0.001). The levels of follicular fluid vitamin D were significantly higher than the levels of serum vitamin D (P < 0.001)
Patients and IVF cycle characteristics by pregnancy outcome
| Parameter | Pregnant | Not pregnant | Live birth | No live birth | ||
|---|---|---|---|---|---|---|
| Number of cycles | 293 | 194 | 261 | 226 | ||
| Age(y) | 31.29 ± 3.53 | 32.63 ± 3.65 | <0.001* | 31.12 ± 3.41 | 32.64 ± 3.71 | <0.001* |
| Duration of infertility(y) | 3.54 ± 2.26 | 3.77 ± 2.43 | 0.284 | 3.45 ± 2.15 | 3.84 ± 2.52 | 0.065 |
| BMI (kg/m2) | 23.25 ± 3.34 | 23.74 ± 3.46 | 0.116 | 23.28 ± 3.34 | 23.62 ± 3.46 | 0.271 |
| AMH (ng/ml) | 5.31 ± 3.76 | 4.83 ± 3.55 | 0.160 | 5.41 ± 3.82 | 4.79 ± 3.50 | 0.065 |
| bFSH (mIU/ml) | 6.98 ± 1.74 | 7.10 ± 1.88 | 0.475 | 6.93 ± 1.74 | 7.14 ± 1.87 | 0.208 |
| Season of blood drawing | ||||||
| Spring ( | 41,54.7% | 34,45.3% | 0.209 | 37,14.2% | 4,12.5% | 0.706 |
| Summer ( | 83, 58.5% | 59,41.5% | 76,29.1% | 7,21.9% | ||
| Autumn ( | 83,68.0% | 39,32.0% | 74,28.4% | 9,28.1% | ||
| Winter ( | 86; 58.1% | 62,41.9% | 74,28.4% | 12,37.5% | ||
| Previous pregnancy | ||||||
| NO ( | 141, 48.1% | 89, 45.9% | 0.628 | 129,49.4% | 106,46.9% | 0.587 |
| Yes ( | 152, 51.9% | 105, 54.1% | 132,50.6% | 120,53.1% | ||
| Infertility diagnosis | ||||||
| Male factor ( | 11,3.8% | 6,3.1% | 0.426 | 10,3.8% | 6,2.7% | 0.688 |
| Tubal factor ( | 193,65.9% | 125,64.4% | 168,64.4% | 150,66.4% | ||
| Mixed ( | 41,14.0% | 21,10.8% | 38,14.6% | 25,11.1% | ||
| Endometriosis ( | 18,6.1% | 11, 5.7% | 16,6.1% | 12,5.3% | ||
| Anovulatory ( | 28,9.6% | 27,13.9% | 26,10.0% | 29,12.8% | ||
| Unexplained ( | 2,0.7% | 4,2.1% | 3,1.1% | 4,1.8% | ||
| COH protocol | ||||||
| Luteal phase agonist ( | 228,77.8% | 138,71.1% | 0.108 | 207,79.3% | 159,70.4% | 0.027* |
| Antagonist ( | 65,22.2% | 56,28.9% | 54,20.7% | 67,29.6% | ||
| Duration of stimulation (d) | 9.08 ± 2.31 | 9.05 ± 2.06 | 0.908 | 9.06 ± 2.26 | 9.07 ± 2.16 | 0.962 |
| Follicle≥16 mm on HCG day | 7.74 ± 3.04 | 7.22 ± 2.96 | 0.059 | 7.78 ± 2.90 | 7.25 ± 3.13 | 0.055 |
| Endometrial thickness on HCG day (mm) | 11.75 ± 2.10 | 11.22 ± 2.24 | 0.008* | 11.82 ± 2.09 | 11.21 ± 2.22 | 0.002* |
| Progestrone on HCG day (ng/ml) | 0.92 ± 0.29 | 0.90 ± 0.33 | 0.578 | 0.92 ± 0.29 | 0.90 ± 0.33 | 0.332 |
| Peak estradiol (pg/ml) | 2602.72 ± 1142.74 | 2436.73 ± 1032.56 | 0.116 | 2625.10 ± 1114.09 | 2436.06 ± 1078.48 | 0.070 |
| Oocytes retrieved ( | 8.39 ± 2.98 | 7.91 ± 3.28 | 0.094 | 8.50 ± 2.95 | 7.85 ± 3.25 | 0.020* |
| Mature oocytes ( | 7.03 ± 2.68 | 6.66 ± 2.99 | 0.156 | 7.15 ± 2.68 | 6.58 ± 2.92 | 0.024* |
| Normal fertilization rate (%) | 72.55 ± 17.70 | 73.19 ± 20.05 | 0.710 | 72.22 ± 17.18 | 73.48 ± 20.23 | 0.456 |
| High quality embryo rate (%) | 59.5% | 57.1% | 0.199 | 58.4% | 51.6% | 0.001* |
| Blastocyst formation rate (%) | 66.33 ± 31.39 | 62.75 ± 34.51 | 0.273 | 66.06 ± 31.59 | 63.61 ± 33.90 | 0.443 |
| Embryos transferred ( | 1.96 ± 0.21 | 1.92 ± 0.28 | 0.082 | 1.96 ± 0.20 | 1.92 ± 0.27 | 0.081 |
*Values are significantly different between groups (P < 0.05)
Serum 25 (OH) D concentrations in relation to clinical outcomes of IVF: univariate and multivariate logistic analysis
| Outcomes | Group1 | Group2 | Group 3 | Group 4 |
|---|---|---|---|---|
| Number of cycles | 216 | 210 | 211 | 211 |
| Clinical pregnancy rate (%) | 59.2% | 57.9% | 60.0% | 63.5% |
| Univariate (OR(95%CI),P) | 1 | 0.947 (0.567–1.581),0.836 | 1.035 (0.618–1.734),0.895 | 1.200 (0.718–2.006),0.486 |
| Multivariatea (OR(95%CI),P) | 1 | 1.007 (0.578–1.752),0.981 | 0.988 (0.562–1.737),0.968 | 1.173 (0.674–2.043),0.573 |
| Implantation rate (%) | 42.9% | 41.4% | 44.5% | 43.9% |
| Univariate (OR(95%CI),P) | 1 | 0.941 (0.651–1.361),0.747 | 1.069 (0.741–1.541),0.722 | 1.043 (0.726–1.499),0.818 |
| Multivariatea (OR(95%CI),P) | 1 | 0.958 (0.647–1.419),0.931 | 1.024 (0.690–1.518),0.907 | 1.021 (0.693–1.506),0.915 |
| Abortion rate (%) | 8.5% | 10.0% | 2.8% | 8.8% |
| Univariate (OR(95%CI),P) | 1 | 1.398 (0.459–4.260),0.556 | 0.637 (0.172–2.362),0.500 | 1.373 (0.463–4.070),0.567 |
| Multivariatea (OR(95%CI),P) | 1 | 1.319 (0.365–4.768),0.673 | 0.732 (0.171–3.126)0.673 | 1.302 (0.373–4.544),0.679 |
| Live birth rate (%) | 53.3% | 48.8% | 56.7% | 55.6% |
| Univariate (OR(95%CI),P) | 1 | 0.833 (0.502–1.381),0.478 | 1.144 (0.688–1.903),0.604 | 1.094 (0.662–1.807),0.726 |
| Multivariatea (OR(95%CI),P) | 1 | 0.876 (0.507–1.515),0.636 | 1.089 (0.624–1.901),0.765 | 1.078 (0.626–1.856),0.787 |
Values are significantly different between groups (P < 0.05)
aAdjusted for maternal age, BMI, AMH, type of infertility, previous pregnancy, seasons when samples were taken, COH protocol, duration of stimulation, number of oocytes retrieved, endometrial thickness, serum progesterone levels on the day of hCG and the number of embryo transferred
Fig. 4ROC curve and performance characteristics for total serum vitamin D measured in patients. a (normal fertilization rate): The area under the ROC curve for vitamin D was 0.674, p = 0.0007. b (clinical repgnancy rate): The area under the ROC curve for vitamin D was 0.521, p = 0.4251. c (live birth rate): The area under the ROC curve for vitamin D was 0.523, p = 0.3822